Loading
Cardiorenal Syndrome / Chronic Kidney Disease / Angiotensin Receptor Antagonists · Journal article
Renal Failure · April 7, 2026
The material analysed did not support any firm read.
This bibliometric analysis examines 254 publications on sacubitril/valsartan in chronic kidney disease from 2013 to 2025, mapping research trends rather than evaluating clinical efficacy. It identifies growing interest in cardiorenal applications and combination therapies but does not provide original clinical evidence or outcomes data.
Bibliometric analysis. 254 peer-reviewed articles published between January 2013 and June 2025 on sacubitril/valsartan in chronic kidney disease. Intervention: Bibliometric analysis of published literature on sacubitril/valsartan in CKD. n = 254. Global literature; China and the United States identified as largest contributors.
254 peer-reviewed articles on sacubitril/valsartan in CKD were retrieved from Web of Science Core Collection (January 2013 to June 2025) The United States showed betweenness centrality of 0.33 in collaboration networks Emerging research themes include combination therapy with SGLT2 inhibitors, precision medicine, and applications in cardiorenal syndrome, CKD, and ESRD
Bibliometric findings reflect publication patterns, not clinical efficacy or safety
This analysis provides no direct clinical evidence but maps the research landscape, identifying persistent knowledge gaps in long-term safety, dialysis dosing, and renoprotective mechanisms. Clinicians should recognize this as a synthesis of publication trends, not a systematic review of clinical efficacy.
This is a bibliometric analysis of published literature, not a primary clinical study, and provides no original outcome data on sacubitril/valsartan efficacy or safety.
As stated by the source record.
Quoted from the source exactly as published.
This analysis provides no direct clinical evidence but maps the research landscape, identifying persistent knowledge gaps in long-term safety, dialysis dosing, and renoprotective mechanisms. Clinicians should recognize this as a synthesis of publication trends, not a systematic review of clinical efficacy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Chronic kidney disease (CKD) is a global health issue with progressive renal decline. Sacubitril-valsartan, the first angiotensin receptor-neprilysin inhibitor (ARNI), offers a novel therapeutic approach with potential renoprotective effects in patients with CKD.Methods. A bibliometric analysis was conducted using 254 peer-reviewed articles retrieved from the Web of Science Core Collection (January 2013 to June 2025). Search terms included 'sacubitril/valsartan' and keywords related to CKD. Data were analyzed and visualized using CiteSpace V6.3.R6, VOSviewer 1.6.20, and R software (Bibliometrix package). Techniques included coauthorship, co-citation, co-occurrence analysis, burst detection, and thematic mapping.Results. The literature on sacubitril/valsartan in CKD has increased steadily over time, with China and the United States contributing the largest number of publications; the United States showed higher betweenness centrality (0.33). Novartis and Harvard University were among the most productive sources, while ESC Heart Failure had the highest number of publications. The New England Journal of Medicine was the most frequently co-cited journal. Keyword and timeline analyses indicate emerging research themes, including combination therapy with SGLT2 inhibitors, precision medicine, and applications in cardiorenal syndrome, CKD, and end stage renal disease (ESRD).Conclusions. This bibliometric analysis delineates the evolving research landscape of sacubitril/valsartan in CKD from 2013 to 2025, highlighting sustained growth, key contributors, and emerging research themes. The findings underscore increasing attention to cardiorenal applications, precision medicine, and combination therapies, while also identifying persistent gaps related to long-term safety, dialysis dosing, and renoprotective mechanisms. These insights provide a structured reference to inform future clinical and translational research in CKD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.